Clinical Trial: A Phase 1b Study of BHV-7000 in Participants With Inherited Erythromelalgia

U.S., Dec. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07262268) titled 'A Phase 1b Study of BHV-7000 in Participants With Inherited Erythromelalgia' on Nov. 17.

Brief Summary: The purpose of this study is to test the potential benefits of BHV-7000 in reducing chronic pain in participants with IEM with a previously demonstrated gain of function mutation in the SCN9A gene.

Study Start Date: Dec., 2025

Study Type: INTERVENTIONAL

Condition: Familial Erythromelalgia

Intervention: DRUG: BHV-7000

Participants will take blinded investigational product (IP) orally once daily

DRUG: Placebo

Matching placebo taken orally once daily

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Biohaven Therapeutics Ltd....